Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. (noted as "HARROW, INC." in request metadata) on October 24, 2014. The report details the entry into a material definitive agreement with Urigen Pharmaceuticals, Inc. regarding the licensing of a pharmaceutical product.
Key Financial Metrics and Agreement Terms
The filing does not provide standard financial statements (revenue, profit, cash flow, or debt) as it is a current report on a specific event. However, it outlines the following financial obligations and commitments:
- License Type: Non-exclusive license for URG101 (a lidocaine and heparin formulation for lower urinary tract disorders), with an option to convert to an exclusive license between the 6-month and 12-month anniversaries of the effective date.
- Royalty Structure: Annual tiered royalties based on net sales, ranging from 15% to 20%, or a minimum amount per dose, whichever is greater.
- Minimum Annual Royalties:
- For the year containing the conversion option window: The greater of 110% of prior existing sublicense royalties (prorated) or $800,000, less royalties paid under existing sublicenses.
- For subsequent years: 110% of the aggregate amount owed in the prior calendar year.
- Commercialization Investment: The Company is obligated to invest $2 million in commercialization efforts, subject to adjustment based on market circumstances.
Material Changes and Outlook
The primary material change is the acquisition of rights to develop and sell URG101 in the U.S. The agreement includes a diligence plan requiring commercially reasonable efforts to develop and commercialize the product. The agreement terminates upon the first commercial sale of the product by Urigen or its affiliates after FDA approval, at which point Imprimis may have the option to become a non-exclusive distributor.
Risks and Contingencies
- Regulatory Approval: The agreement's duration and exclusivity options are contingent on FDA approval granted to Urigen.
- Termination: The agreement may be terminated earlier under certain circumstances specified in the contract.
- Market Circumstances: The $2 million investment timeline and amount are adjustable dependent on market conditions.
Investor Verification Checklist
- Verify the status of the FDA approval process for URG101, as this triggers potential termination of the agreement.
- Confirm the specific terms of the "Existing Sublicenses" referenced in the minimum royalty calculation.
- Review the attached Exhibit 10.1 (License Agreement) for the full text of the diligence plan and termination clauses.
- Monitor the Company's cash position to ensure it can meet the $2 million commercialization investment commitment.